Role of G-protein coupled receptors in cardiovascular diseases

Introduction

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. CVDs are divided into two categories, vascular diseases and heart diseases (1). Vascular diseases include hypertension, atherosclerosis, aortic aneurysms, and vascular calcification (2), while the major components of heart diseases are ischemic heart diseases, rheumatic heart diseases, cardiomyopathy, and myocarditis (3). There are numerous options for treating CVDs, such as lipid-lowering drugs, antihypertensive drugs, antiplatelet and anticoagulant therapies. Despite the effectiveness of these approaches, there is still a long way from curing CVDs (4). Thus, it is crucial to find novel therapeutic targets and develop new drugs to treat CVDs.

G-protein-coupled receptors (GPCRs), which are the most prominent receptor family among all cell surface proteins (5), play essential roles in various human physiological and pathological processes (6). GPCRs contain seven transmembrane α-helices and are coupled with heterotrimeric GTP-binding proteins (G proteins), which are composed of Gα, Gβ, and Gγ subunits. Depending on the difference between Gα subunits, G proteins can be divided into four categories that play different roles. First of all, Gαs can generate the second messenger cyclic-3′,5′-adenosine monophosphate (cAMP) by activating adenylate cyclase, while Gαi/o exerts the opposite effect. Then Gαq/11 activates phospholipase C (PLC) to produce the second messenger inositol 1,4,5-trisphosphate (IP3). Finally, Gα12/13 can regulate downstream signals through the small GTPase Rho (7).

GPCRs are widely expressed in the cardiovascular system and play crucial roles in regulating cardiovascular function and morphology (8). β-Adrenergic receptors (βARs) and angiotensin II type 1 receptors (AT1Rs) are important GPCRs in cardiovascular function. In addition, there are many other GPCRs, such as apelin receptor (APJ), lysophosphatidic acid receptor (LPARs) and endothelin receptors (ETAR and ETBR), that play important roles in CVDs. Chronic activation by their endogenous ligands increases the workload of the heart, leading to harmful effects such as heart failure (HF) (9). For these reasons, β-blockers and angiotensin-converting enzyme inhibitors are recommended by WHO as essential medicines for patients with CVDs. Furthermore, roughly one-third of all currently used drugs in cardiovascular practice target GPCRs (10). In this review, we summarize the role of GPCRs in CVDs from both vascular diseases and heart diseases, providing new ideas for the treatment of cardiovascular diseases and the development of innovative drugs (Table 1).

www.frontiersin.org

Table 1. GPCRs in cardiovascular system and cardiovascular disease.

GPCRs in vascular function and disease GPCRs and vascular function

Vascular homeostasis is essential for maintaining the health of the body. Smooth muscle cells (SMCs) are a major structural component of the vessel wall, regulating vascular tone to maintain intravascular pressure (110). Meanwhile, endothelial cells (ECs) are critical regulators of vascular inflammation, thrombophlebitis, permeability, and vascular remodeling (111). Under normal conditions, SMCs and ECs exert a protective role, maintaining vascular stability. However, during the development of vascular disease, the dysfunction of ECs and the dedifferentiation of SMCs promote pathological changes in the vasculature, thereby accelerating the process of vascular diseases. Single-cell GPCR expression analysis demonstrates that the expression of GPCRs in ECs and SMCs is highly heterogeneous. Vascular diseases such as atherosclerosis lead to characteristic changes in the expression of GPCRs (112). Thus, in the vascular system, GPCRs are critical regulators.

GPCRs regulate blood pressure by modulating the dynamic balance of vasoconstriction and relaxation (113, 114). Gαq/11-coupled GPCRs and Gα12/13-coupled GPCRs cause vasoconstriction via Ca2+ and RhoA, respectively. Conversely, Gαs-coupled GPCRs can generate cAMP, and then promote blood vessel relaxation (115, 116). One typical example is that angiotensin II (AngII) binds to and activates angiotensin receptors (AT1R and AT2R), causing the smooth muscle to contract (11). And α1-adrenergic receptor (α1-AR), mainly expressed in SMCs, has a similar function (117). The APJ is highly expressed in cardiovascular tissues, and the apelin/APJ system is vital for regulating vascular tone (45, 46). Apelin/APJ system can inhibit the BKCa signaling pathway (118), increase the phosphorylation of MLC (119), or cooperate with α1-AR to promote vasoconstriction (19). However, the apelin/APJ system can induce vasodilatation by stimulating the release of nitric oxide (NO) (47, 120). This different regulation depends on the type of blood vessels and pathological condition (45). Besides, many other GPCRs are implicated in the regulation of vasoconstriction and relaxation. LPA stimulates LPA receptor 1 (LPAR1), then activates PLC and releases NO to induce vasorelaxation. In addition, activation of LPAR1 can also produce thromboxane A2 (TxA2), which can bind to prostaglandin receptors, leading to vasoconstriction (5254). The endothelin system includes two GPCRs: endothelin receptor A (ETAR) and B (ETBR). Endothelin 1 (ET-1) can promote vasoconstriction by activating ETAR or promote vasodilation by activating ETBR (59). Recent studies have shown that the binding of the orphan receptor GPR75 to 20-hydroxyeicosatetraenoic acid (20-HETE) activates the Gαq/11 protein, which causes vasoconstriction (69). And short-chain fatty acids (SCFAs) can activate GPR41 to induce vasodilation (70). In conclusion, GPCRs are critical regulators of vascular tone.

Normal vascular endothelial function is highly crucial for vascular homeostasis. Endothelial dysfunction leads to the destruction of cell connections, vascular leakage, tissue edema, and organ failure (111, 121). Vascular endothelial dysfunction is caused by inflammation, and GPCRs play an essential role in this process (122). Multiple GPCRs agonists, including thrombin, histamine, and prostaglandin E2, stimulate robust p38 autophosphorylation to promote endothelial inflammatory responses (123). Purinergic GPCRs (P2Ys) are widely expressed in the cardiovascular system. P2Y1, P2Y2, P2Y4, and P2Y6 can promote vascular inflammation and reduce endothelial barrier function through the Gαq-PLC pathway (124). Protease-activated receptors (PARs) are specific GPCRs that can be cleaved by serine proteases thrombin or trypsin and then regulate downstream signaling pathways. The sustained activation of PAR1 promotes the disruption of endothelial junction proteins, increases endothelial permeability and plasma extravasation, and leads to endothelial dysfunction (67). In contrast, activation of GPR120, a recently identified omega-3 fatty acid receptor, inhibits oxidative stress and inflammation by suppressing the production of reactive oxygen species (ROS) and the expression of pro-inflammatory cytokines. It also can protect vascular endothelial function by preventing monocyte attachment to endothelial cells (71).

The flow of blood causes shear stress, which is a mechanical stimulus. Mechanical stimuli can be sensed by cells and converted into biochemical signals to inspire diverse cellular functions (125, 126). Some GPCRs are initial sensors of mechanical stimulation, they can be activated by shear stress to regulate downstream signals. For instance, GPR68, a mechanosensor expressed in ECs, is significantly responsive to shear stress and is required for ECs' shear stress sensitivity. After the absence of GPR68 in mice, the vasodilation response brought about by the increase in blood flow was disrupted, suggesting that GPR68 is involved in flow-mediated vasodilation and remodeling (73, 74). Similar to GPR68, the H1 histamine receptor (H1R) is mechanosensitive Gαq/11 coupled GPCR highly expressed in ECs. Shear stress activates H1R in an agonist-independent manner, leading to vasodilation (75). APJ is another GPCR that can be activated by mechanical stimulation. Flow-induced signaling through APJ is crucial for cell morphology, endothelial elasticity, and cellular adhesion. Deleting APJ not only impairs the elasticity and cell adhesion of ECs but also alters the remodeling of actin filaments and the distribution of vinculin particles (48).

In summary, GPCRs play an important role in regulating vascular tension, maintaining vascular endothelial barrier function, and sensing blood flow shear stress.

GPCRs and atherosclerosis

Atherosclerosis is a progressive disease. The accumulation of lipids, fibers, or cell debris on the arterial intima interferes normal function of blood vessels and impedes blood flow. In severe cases, it can lead to myocardial infarction or stroke (127). Atherosclerosis can be seen as a response to injury and is a chronic inflammatory disease of blood vessels. Endothelial dysfunction caused by vascular inflammation initiates the process of atherosclerosis. In the presence of inflammatory factors, SMCs migrate to the vascular intima and then proliferate, resulting in atherosclerotic plaques (128, 129). Endothelial dysfunction and the proliferation and migration of SMCs are the fundamental factors of atherosclerosis. Many GPCRs play an essential role in vascular endothelial dysfunction, therefore significantly influencing on the atherosclerotic process.

The role of P2Ys in atherosclerosis can be anticipated due to their role in endothelial dysfunction (130). A typical example is P2Y2. The ATP released by oxidized low-density lipoprotein (LDL) activates P2Y2, therefore promoting vascular inflammation, ensuring penetration and adhesion of monocytes, and accelerating the process of atherosclerosis (64). In addition, P2Y6 is upregulated in atherosclerotic lesions, suggesting that it may also promote atherosclerosis. Due to reduced vascular inflammation, P2Y6-deficient mice have a slowed atherosclerotic process (65). LPA accumulates in atherosclerosis, and the expression of LPAR1-LPAR6 in human arterial plaques and normal arteries is significantly different, suggesting that LPARs may play a role in atherosclerosis (131, 132). Activation of LPAR1 and LPAR3 can promote the expression of hypoxia-inducible factor 1 subunit alpha (HIF-1α), then upregulate C-X-C motif chemokine ligand 1 (CXCL1) in cells, thereby accelerating atherosclerosis (133). LPAR6 can induce actin stress crack formation through the RhoA/ROCK pathway to increase endothelial permeability and advance the occurrence of atherosclerosis (55). Furthermore, LPAR5 activates the TGFBR1, which stimulates the glycosaminoglycan (GAG) chain elongation, resulting in the early pathogenesis of atherosclerosis (56). The interaction between chemokines and their GPCR-type receptors (CRKs) is an element that promotes atherosclerosis. CXC-motif chemokine receptor-4 (CXCR4) (78), CC chemokine receptor 2 (CCR2) (80), and C-X3-C Motif Chemokine Receptor 1 (CX3CR1) (81) accelerate atherosclerosis by promoting vascular inflammation.

The proliferation and migration of SMCs accelerate the occurrence of atherosclerosis, and GPCRs also regulate this process. LPARs play a vital role in the dedifferentiation, proliferation, and migration of SMCs (52). LPA promotes the dedifferentiation of SMCs through LPAR3 (57) and promotes SMC proliferation and migration through LPAR1 and LAPR2 (58). And in-depth studies suggest that LPA may accelerate the atherosclerosis process by activating Gαq/11-coupled GPCRs to promote the proliferation and migration of SMCs (134, 135). Yes-associated protein (YAP) signaling pathway is a crucial regulator of the proliferation and migration of SMCs (136). Depending on the difference of the coupled G protein, GPCRs have different effects on the regulation of YAP. Briefly, Gαi/o, Gαq/11, and Gα12/13 can activate YAP, while Gαs exerts an inhibitory effect (137). For instance, the thromboxane A2 receptor (TP) (82), AT1R (138), and ETAR (60) can activate YAP, then promote the proliferation and migration of SMCs. Activation of APJ by apelin promotes the proliferation of SMCs, while the knockout of APJ reduces the production of ROS and the formation of atherosclerosis (49). By promoting the activity of growth factor receptors EGFR and HGFR, the α2-adrenergic receptor (α2-AR) promotes the proliferation of SMCs cells (20). Furthermore, the Glucagon-like peptide 1 receptor (GLP-1R) is located in the nucleus of rat SMCs, and artificially keeping it in the cytoplasm can promote the proliferation of SMCs (83). Together, these studies show that GPCRs are of profound significance to the occurrence and development of atherosclerosis, and the development of drugs targeting GPCRs to treat atherosclerosis is very necessary.

GPCRs in heart function and disease GPCRs and heart function

The heart principal function is to pump blood to the circulation of the various organs and systems of the human body to achieve the purpose of oxygen supply and nutrient exchange. The normal development of the heart is of great importance. Abnormal heart development leads to heart malformations and congenital heart disease, affecting human life and health (139, 140). After years of research, a large number of pathways and processes that play a regulatory role in the development of the heart have come to light. Among them, GPCRs are regulators that cannot be neglected (90). Sphingosine 1-phosphate (S1P) is a lipid with biological activity, and the activation of its receptors S1P receptors (S1PRs) is essential in the normal development of the heart (87). Mice with global loss of S1PR1 will die 12.5–14.5 days post-coitus due to cardiovascular defects (88). In addition, knocking out S1PR1 in mouse cardiomyocytes will affect standard ventricular compaction, septation, and embryo survival, indicating that S1PR1 in cardiomyocytes is required for the normal development of the heart (89). The apelin-APJ system is an essential regulator of the cardiovascular system. Loss of APJ leads to abnormal development of myocardial progenitor and defects in heart development (50, 51). Apela is an endogenous ligand of APJ newly discovered in recent years (141), and the absence of apela gene also leads to early deformation of heart development (142, 143). Many other GPCRs are also important in heart development. Prokineticin receptor-1 (PKR1) (90), C-X-C motif chemokine receptor 7 (CXCR7) (92, 93), 5-hydroxytryptamine receptor 2B (5-HT2B) (144), and atypical chemokine receptor (ACKR) (145) are critical to the development of the heart, and the absence of either of them leads to incomplete heart development and thus death in mice.

The heart's contraction is a complex process involving action potentials, contractile proteins, and excitation-contraction coupling, which has been thoroughly reviewed by predecessors (146150). Heart contractility is extremely important to the pumping function of the heart, and the decline of contractility can lead to HF, which results in sudden death (147). GPCRs expressed in the human myocardium have both positive and negative regulatory effects on heart contractility. AR family mainly includes five receptors, α1, α2, β1, β2, and β3 (117). These five receptors are all expressed in the heart, and the regulatory role of βARs in the heart is crucial. β1-AR accounts for about 80% of the βARs in the heart, followed by β2-AR, accounting for 15%–18%, and the remaining β3-AR (10). Activation of β1-AR or β2-AR will activate Gαs protein and promote the production of cAMP. Then cAMP acts on protein kinase A (PKA), thereby causing heart contraction (21, 151). Conversely, activation of β3-AR promotes cardiac relaxation through the release of NO (22). Besides, α1-AR (23) and α2-AR (24) perform functions that promote or inhibit cardiac contraction, respectively. In addition, using corticotropin-releasing hormone (CRH) to activate CRH receptor 2 (CRH-R2) in mice can promote heart contraction through a variety of signaling pathways, including adenylate cyclase, PKC, and PKA (94). And the binding of myosuppressin (MS) to its receptor can decrease heart contractility to a great extent (152). In summary, the strategic role of GPCRs in heart development and contraction is evident.

GPCRs and cardiac ischemia-reperfusion injury

Ischemic heart disease occupies an essential position in all types of heart disease, and its fatality rate has reached almost half of all CVDs, and it is the leading cause of death around the world (3). The ischemia-reperfusion (IR) process is a pathological phenomenon, which refers to first restricting the blood supply to the organ, then restoring the perfusion and corresponding oxygen supply (153). Heart IR will cause many deaths of cardiomyocytes and induce severe autoimmune responses, which may lead to long-term cardiac dysfunction (153, 154). Therefore, effective interventions to limit IR injury (IRI) are critical to protecting the heart. GPCRs have been proven to play a significant role in inhibiting IRI and protecting the heart. The opioid receptor (OR) family is a cardioprotective system, and opioid preconditioning has shown a strong protective effect on IRI (155). δ opioid receptors (DOR) and κ opioid receptors (KOR) are expressed in human cardiomyocytes, while the expression of μ opioid receptors (MOR) is dependent on species (95). During IR, ORs are vital determinants of ischemia and hypoxia tolerance; opioid levels are upregulated in heart ischemic, which leads to the activation of ORs and induces cardioprotective responses (96). ORs preconditioning effects activate a series of downstream signal pathways through the Gαi/o-PKC pathway to protect mitochondrial function, inhibit cell death signals, and achieve the purpose of protecting the heart (9699). Adenosine receptors are another GPCR family that can protect the heart in IR. Studies have shown that the four subtypes of adenosine receptors, A1, A2A, A2B, and A3, have beneficial effects in protecting the heart (156). Activating A1 and A3 adenosine receptors before ischemia can initiate the ischemic preconditioning response, improve the ischemia tolerance of the heart, and avoid heart damage (100, 101). At the same time, the A2 adenosine receptors protect the heart during reperfusion, and the synergistic effect of A2A and A2B may play a non-negligible role in avoiding reperfusion injury (102, 103). S1P is released in the ischemic damaged heart and then binds to S1PRs to protect the heart from IRI by the Gα12/13-RhoA-protein kinase D (PKD) pathway (157, 158). However, some GPCRs can exacerbate the IRI of the heart, and the most prominent example is the calcium-sensing receptor (CaSR). CasR is widely expressed throughout the body, and its primary function is to maintain a constant concentration of extracellular ionized Ca2+ (108). Research has shown that the activation of CaSR by IR induces mitochondrial apoptosis, which promotes cardiomyocyte apoptosis, causing heart damage (109). In short, GPCRs have a critical role in the positive and negative regulation of IRI. Targeting GPCRs to prevent heart damage, alleviate heart disease, and avoid HF is a promising treatment.

Conclusion

Since CVDs are the leading cause of death globally, it is essential to find therapeutic targets for CVDs and develop drugs to treat CVDs. Because of their signal transduction function, GPCRs play a critical role in the occurrence and development of CVDs (Figure 1). In terms of vascular function and disease, GPCRs can receive a variety of extracellular stimuli, including their ligands or mechanical stress, regulate vascular tension and endothelial function, then positively or negatively adjust vascular diseases such as hypertension and atherosclerosis. There are significant gender differences in the occurrence of CVDs, with a higher incidence of CVDs in men compared to women (159). Multiple GPCRs play an integral role in this phenomenon, the most prominent is the G protein-coupled estrogen receptor (GPER), whose activation by estrogen is a key factor in female-specific cardiovascular protection (160). In addition, the orphan receptor GPR37L1 is also involved in the sex differences in CVDs. Mice lacking GPR37L1 exhibited female-specific increases in systolic, diastolic and mean arterial pressure. However, the gender issues on GPCR functions in CVDs are still not clear and further studies are still needed (161163). In addition, GPCRs regulate the development and function of the heart, and further participate in heart diseases as a target for treatment. Finally, an understanding of the roles of these GPCRs in the cardiovascular system and CVDs will provide new insights into GPCRs and new ideas for fully exploiting the enormous treasure trove of GPCRs.

www.frontiersin.org

Figure 1. GPCRs in cardiovascular system and cardiovascular disease. GPCRs play an important role in the cardiovascular system and are involved in a variety of cardiovascular disease processes. AT1R, angiotensin II type 1 receptor; α1-AR, α1-adrenergic receptor; α2-AR, α2-adrenergic receptor; β1-AR, β1-adrenergic receptor; β2-AR, β2-adrenergic receptor; β3-AR, β3-adrenergic receptor; ETAR, endothelin receptor A; APJ, apelin receptor; LPAR1, lysophosphatidic acid receptor 1; LPAR3, lysophosphatidic acid receptor 3; LPAR6, lysophosphatidic acid receptor 6; H1R, H1 histamine receptor; P2Y1, purinergic receptor P2Y1; P2Y2, purinergic receptor P2Y2; P2Y4, purinergic receptor P2Y4; P2Y6, purinergic receptor P2Y6; CXCR4, CXC-motif chemokine receptor-4; CCR2, combining CC chemokine receptor 2; PAR1, Protease-activated receptor 1; TP, thromboxane A2 receptor; S1PR1, Sphingosine 1-phosphate receptor 1; PKR1, Prokineticin receptor-1; CRH-R2, corticotropin-releasing hormone receptor 2; DOR, δ opioid receptor; KOR, κ opioid receptor; A1, adenosine A1 receptor; A2A, adenosine A2a receptor; A2B, adenosine A2b receptor; A3, adenosine A3 receptor; CasR, calcium-sensing receptor; PLC, phospholipase C; MLC, myosin light chain; cAMP, cyclic-3′,5′-adenosine monophosphate; PKA, protein kinase A; NO, nitric oxide; HIF-1α, hypoxia inducible factor 1 subunit alpha; CXCL1, C-X-C motif chemokine ligand 1; YAP, Yes-associated protein; EGFR, epidermal growth factor receptor; SMCs, smooth muscle cells.

Author contributions

YL and BL: writing—original draft preparation; Y-DW and W-DC: writing—revision, review and editing, supervision and funding acquisition. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by the National Natural Science Foundation of China (grant no. 81970551) and National Key R&D Program of China (2021YFC2103900) to Y-DW, the National Natural Science Foundation of China (grant no. 81970726), Henan Provincial Natural Science Foundation (grant no.182300410323), Program for Science & Technology Innovation Talents in Universities of Henan Province (HASTIT, grant no. 13HASTIT024), Plan for Scientific Innovation Talent of Henan Province, and National College Student Innovation and Entrepreneurship Training Program (grant no. 202010475032) to W-DC.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Yu Y, Su X, Qin Q, Hou Y, Zhang X, Zhang H, et al. Yes-associated protein and transcriptional coactivator with pdz-binding motif as new targets in cardiovascular diseases. Pharmacol Res. (2020) 159:105009. doi: 10.1016/j.phrs.2020.105009

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Ladich E, Yahagi K, Romero ME, Virmani R. Vascular diseases: aortitis, aortic aneurysms, and vascular calcification. Cardiovasc Pathol. (2016) 25(5):432–41. doi: 10.1016/j.carpath.2016.07.002

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. (2017) 121(6):677–94. doi: 10.1161/circresaha.117.308903

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Flora GD, Nayak MK. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des. (2019) 25(38):4063–84. doi: 10.2174/1381612825666190925163827

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Touyz RM. The role of angiotensin ii in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. (2003) 5(2):155–64. doi: 10.1007/s11906-003-0073-2

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the At1 receptor antagonist valsartan on the angiotensin ii-renin feedback interruption. J Am Soc Nephrol. (2004) 15(12):3126–33. doi: 10.1097/01.ASN.0000146686.35541.29

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin ii type At1 receptor antagonist. J Hypertens Suppl. (2001) 19(1):S3–S14. doi: 10.1097/00004872-200106001-00002

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Dickstein K, Timmermans P, Segal R. Losartan: a selective angiotensin ii type 1 (At1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. (1998) 7(11):1897–914. doi: 10.1517/13543784.7.11.1897

PubMed Abstract | CrossRef Full Text | Google Scholar

15. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, et al. Hemodynamic and biochemical effects of the At1 receptor antagonist irbesartan in hypertension. Hypertension. (1995) 25(1):22–9. doi: 10.1161/01.hyp.25.1.22

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl. (2006) 24(1):S23–S30. doi: 10.1097/01.hjh.0000220403.61493.18

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective At1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. Tees study group. J Hypertens. (1999) 17(2):293–302. doi: 10.1097/00004872-199917020-00015

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Jones JD, Jackson SH, Agboton C, Martin TS. Azilsartan medoxomil (edarbi): the eighth angiotensin ii receptor blocker. P T. (2011) 36(10):634–40.22346296

PubMed Abstract | Google Scholar

19. Nagano K, Kwon C, Ishida J, Hashimoto T, Kim JD, Kishikawa N, et al. Cooperative action of apj and Α1a-adrenergic receptor in vascular smooth muscle cells induces vasoconstriction. J Biochem. (2019) 166(5):383–92. doi: 10.1093/jb/mvz071

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Huhtinen A, Hongisto V, Laiho A, Löyttyniemi E, Pijnenburg D, Scheinin M. Gene expression profiles and signaling mechanisms in Α(2b)-adrenoceptor-evoked proliferation of vascular smooth muscle cells. BMC Syst Biol. (2017) 11(1):65. doi: 10.1186/s12918-017-0439-8

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Moens AL, Yang R, Watts VL, Barouch LA. Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol. (2010) 48(6):1088–95. doi: 10.1016/j.yjmcc.2010.02.011

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med. (2007) 13(12):503–11. doi: 10.1016/j.molmed.2007.10.005

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Cohen ML, Berkowitz BA. Decreased vascular relaxation in hypertension. J Pharmacol Exp Ther. (1976) 196(2):396–406.176346

PubMed Abstract | Google Scholar

26. Bernstein JS, Ebert TJ, Stowe DF, Schmeling WT, Nelson MA, Woods MP. Partial attenuation of hemodynamic responses to rapid sequence induction and intubation with labetalol. J Clin Anesth. (1989) 1(6):444–51. doi: 10.1016/0952-8180(89)90009-3

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Korneyev AY, Cincotta AH. Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. (1996) 58(12):241–8. doi: 10.1016/0024-3205(96)00053-7

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A. Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. (2010) 65(12):1200–5. doi: 10.1111/j.1365-2044.2010.06559.x

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Zeng A, Yuan B, Wang C, Yang G, He L. Frontal analysis of cell-membrane chromatography for determination of drug-alpha(1d) adrenergic receptor affinity. J Chromatogr B Analyt Technol Biomed Life Sci. (2009) 877(20–21):1833–7. doi: 10.1016/j.jchromb.2009.05.021

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Altenbach RJ, Khilevich A, Meyer MD, Buckner SA, Milicic I, Daza AV, et al. N-[3-(1h-Imidazol-4-ylmethyl)phenyl]ethanesulfonamide (Abt-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem. (2002) 45(20):4395–7. doi: 10.1021/jm025550h

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1d- and alpha1b-adrenergic receptors. Cardiovasc Res. (2004) 63(4):662–72. doi: 10.1016/j.cardiores.2004.05.014

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Sengupta JN, Hamada A, Miller DD, Patil PN. Interaction of enantiomers of hydroxy tolazoline with adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. (1987) 335(4):391–6. doi: 10.1007/BF00165553

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Song W, Zhang Y, Xia L, Liu G. Effects of some mexiletine derivatives on alpha 1-adrenoceptors. Yao Xue Xue Bao. (1998) 33(2):102–5.11938943

PubMed Abstract | Google Scholar

34. Tatsuta M, Iishi H, Baba M, Yano H, Sakai N, Uehara H, et al. Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in wistar rats. Int J Cancer. (1998) 77(3):467–9. doi: 10.1002/(sici)1097-0215(19980729)77:3%3C467::aid-ijc25%3E3.0.co;2-3

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A. Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. (2001) 276(33):31279–84. doi: 10.1074/jbc.M104167200

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Rudoy CA, Van Bockstaele EJ. Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. (2007) 31(5):1119–29. doi: 10.1016/j.pnpbp.2007.04.005

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. (2003) 74(1):44–52. doi: 10.1016/S0009-9236(03)00068-7

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, et al. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. (2007) 81(5):399–404. doi: 10.1016/j.lfs.2007.06.003

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Wang T, Kaumann AJ, Brown MJ. (–)-Timolol is a more potent antagonist of the positive inotropic effects of (–)-adrenaline than of those of (–)-noradrenaline in human atrium. Br J Clin Pharmacol. (1996) 42(2):217–23. doi: 10.1046/j.1365-2125.1996.39412.x

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Lipworth BJ, Irvine NA, McDevitt DG. A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. (1991) 40(2):135–9. doi: 10.1007/BF00280067

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Nichols AJ, Gellai M, Ruffolo RR Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. (1991) 5(1):25–38. doi: 10.1111/j.1472-8206.1991.tb00698.x

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Doggrell SA. The effects of (+/−)-, (+)-, and (−)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. (1993) 5(1):8–14. doi: 10.1002/chir.530050103

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Berg T, Piercey BW, Jensen J. Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension. (2010) 55(5):1224–30. doi: 10.1161/HYPERTENSIONAHA.109.149286

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]Apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. (2009) 54(3):598–604. doi: 10.1161/hypertensionaha.109.134619

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Strohbach A, Pennewitz M, Glaubitz M, Palankar R, Groß S, Lorenz F, et al. The apelin receptor influences biomechanical and morphological properties of endothelial cells. J Cell Physiol. (2018) 233(8):6250–61. doi: 10.1002/jcp.26496

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol. (2007) 171(5):1705–12. doi: 10.2353/ajpath.2007.070471

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Charo DN, Ho M, Fajardo G, Kawana M, Kundu RK, Sheikh AY, et al. Endogenous regulation of cardiovascular function by apelin-apj. Am J Physiol Heart Circ Physiol. (2009) 297(5):H1904–13. doi: 10.1152/ajpheart.00686.2009

PubMed Abstract | CrossRef Full Text | Google Scholar

留言 (0)

沒有登入
gif